Impact and management of Campylobacter in human medicine — European perspective

Kist, Manfred

doi:10.1016/s1201-9712(02)90183-9

Cited by 12 publications

(6 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When patients suffer from recurrent or systemic Campylobacter infection, antimicrobial treatment is indicated. However, an increase in antimicrobial resistance, especially fluoroquinolone resistance, in both human and animal isolates has been observed over the last decade (93,167).…”

Section: Pathology and Pathophysiology Of Campylobacter Infectionmentioning

confidence: 99%

Host-Pathogen Interactions inCampylobacterInfections: the Host Perspective

et al. 2008

View full text Add to dashboard Cite

SUMMARY Campylobacter is a major cause of acute bacterial diarrhea in humans worldwide. This study was aimed at summarizing the current understanding of host mechanisms involved in the defense against Campylobacter by evaluating data available from three sources: (i) epidemiological observations, (ii) observations of patients, and (iii) experimental observations including observations of animal models and human volunteer studies. Analysis of available data clearly indicates that an effective immune system is crucial for the host defense against Campylobacter infection. Innate, cell-mediated, and humoral immune responses are induced during Campylobacter infection, but the relative importance of these mechanisms in conferring protective immunity against reinfection is unclear. Frequent exposure to Campylobacter does lead to the induction of short-term protection against disease but most probably not against colonization. Recent progress in the development of more suitable animal models for studying Campylobacter infection has opened up possibilities to study the importance of innate and adaptive immunity during infection and in protection against reinfection. In addition, advances in genomics and proteomics technologies will enable more detailed molecular studies. Such studies combined with better integration of host and pathogen research driven by epidemiological findings may truly advance our understanding of Campylobacter infection in humans.

show abstract

Section: Pathology and Pathophysiology Of Campylobacter Infectionmentioning

confidence: 99%

Host-Pathogen Interactions inCampylobacterInfections: the Host Perspective

et al. 2008

View full text Add to dashboard Cite

show abstract

“…The disease is self-limiting in most cases, but patients at risk, such as young children, elderly people and immune-incompetent patients, require medication beyond fluid replacement, as extended diarrhoea or extraintestinal complications are more common in these cases [4]. In most European countries, treatment of campylobacteriosis with macrolides is recommended as the first choice [5]. In the USA, fluoroquinolones are frequently used as treatment of diarrhoea without bacteriological confirmation of the causative agent, as they are highly effective against Escherichia coli and Salmonella infections [6].…”

Section: Introductionmentioning

confidence: 99%

Re-analysis of the risks attributed to ciprofloxacin-resistant Campylobacter jejuni infections

Wassenaar

Kist

Jong

2007

International Journal of Antimicrobial Agents

Self Cite

View full text Add to dashboard Cite

“…In both Europe and the United States, the drug of choice for treatment-once the diagnosis has been established-is a macrolide (e.g., erythromycin) [2][3][4]. This often poses a therapeutic dilemma, because erythromycin appears to be effective only if it is given early in the course of illness [6].…”

mentioning

confidence: 99%